Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	4.36	8.4	0.03
Cash & Short-Term Investments	4.36	8.4	0.03
Cash Growth	-52.09%	25685.61%	-
Prepaid Expenses	0.19	0.09	0.02
Other Current Assets	0.12	-	0.67
Total Current Assets	4.67	8.49	0.73
Property, Plant & Equipment	0	0.02	0.04
Other Long-Term Assets	0	0	0.01
Total Assets	4.68	8.52	0.78
Accounts Payable	0.5	0.17	0.4
Accrued Expenses	0.77	0.64	0.86
Short-Term Debt	-	-	0.04
Current Portion of Leases	0	0.02	0.02
Total Current Liabilities	1.27	0.83	1.33
Long-Term Debt	-	-	0.55
Long-Term Leases	-	-	0.02
Other Long-Term Liabilities	-	-	4.42
Total Liabilities	1.27	0.83	6.33
Common Stock	0	0.01	0.01
Additional Paid-In Capital	24.95	22.75	1.15
Retained Earnings	-21.54	-15.07	-6.71
Shareholders' Equity	3.41	7.69	-5.55
Total Liabilities & Equity	4.68	8.52	0.78
Total Debt	0	0.02	0.64
Net Cash (Debt)	4.36	8.38	-0.61
Net Cash Per Share	4.05	9.32	-1.16
Filing Date Shares Outstanding	1.78	1.07	0.78
Total Common Shares Outstanding	1.23	0.87	0.55
Working Capital	3.41	7.67	-0.61
Book Value Per Share	2.76	8.86	-10.16
Tangible Book Value	3.41	7.69	-5.55
Tangible Book Value Per Share	2.76	8.86	-10.16

Source: S&P Capital IQ. Standard template. Financial Sources.